secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0000950170-24-015213
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Q2 net loss $1.0M; starts REM-001 CMBC study, explores strategic alternatives
--------------------------------------------------------------------------------

- Q2 net loss $1.0M ($0.24/share) vs $3.5M ($2.10/share) year earlier; R&D fell to $0.1M from $2.1M.
- Cash $0.7M at Dec 31, 2023; raised $6.1M net via ATM from Jan 1-Feb 12, 2024.
- Initiated 15-patient REM-001 study in cutaneous metastatic breast cancer; costs covered by $2.0M SBIR grant from NIH.
- Board reviewing strategic alternatives to maximize stockholder value; Ladenburg Thalmann engaged as financial advisor (Dec 2023).
- VAL-083 development terminated after failure in GBM AGILE study (Oct 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/0000950170-24-015213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024015213/ktra-20240214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-015213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer